TFA Therapeutics, Inc.
RAJAF· OTC
RAJAFTFA Therapeutics, Inc.
Source filing unavailable
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|
| Revenue | $315.50K | — |
| Net Income | $901.17K | -$77.05K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TFA Therapeutics, Inc. · CIK 1885680 · Engraved from SEC EDGAR
